OR WAIT 15 SECS
Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.
Bayer announced on Jan. 7, 2021 that it has entered into an agreement with CureVac, a German biopharmaceutical company, to support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.
Under the terms of the agreement, CureVac will be the marketing authorization holder for the vaccine, while Bayer has the option to hold the title in markets outside of Europe, Bayer said in a company press release. Additionally, Bayer will support CureVac with country operations within the European Union and other markets
“The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate,” said Stefan Oelrich, member of the board of management, Bayer AG, and president of Bayer’s Pharmaceuticals Division, in the press release. “We are highly committed to making our capabilities and networks available to help end this pandemic.”
“We are very happy to join forces with Bayer, whose expertise and infrastructure will help us make our vaccine candidate CVnCoV even more rapidly available to as many people as possible,” added Dr. Franz-Werner Haas, CEO of CureVac, in the press release. “Building on the positive data we have seen so far with CVnCoV, we now also have another strong partner on our side to get the vaccine to the people who need it following the receipt of the requisite regulatory approvals.”